Torsades de pointes induced by transesophageal atrial stimulation after administration of almokalant

International Journal of Cardiology

Volumn 53, Issue 3, 1996, Pages 311-313

  Darpo B ^a   Allared, M ^b   Edvardsson, N ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Almokalant; Torsades de pointes; Transesophageal atrial stimulation; Wolff Parkinson White syndrome

Indexed keywords

ALMOKALANT;

ADULT; ARTICLE; CASE REPORT; DEFIBRILLATION; ELECTROCARDIOGRAM; FEMALE; HEART STIMULATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; TORSADE DES POINTES; WOLFF PARKINSON WHITE SYNDROME;

EID: 0029888399     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-5273(95)02540-5     Document Type: Article

References (7)

1. Sager P, Nademanee K, Antimisiaris M et al. Antiarrhythmic effects of selective prolongation of refractoriness: electrophysiological actions of sematilide HCl in humans. Circulation 1993; 88: 1072-1082.
2. Brachmann J, Haverkamp W, Johns J, Zehender M, Kingma HG, Wiecha J. The efficacy and safety of oral dofetilide in patients with sustained ventricular tachycardia. Circulation 1992; 86 (Suppl.): I-265.
3. Carmeliet E: Use-dependant block and use-dependant unblock of the delayed K+ current by almokalant in rabbit ventricular myocytes. Circ Res 1993; 73: 857-868.
4. Darpö B, Edvardsson N. Effect of almokalant, a selective potassium channel blocker, on the termination and inducibility of paroxysmal supraventricular tachycardias: a study in patients with Wolff-Parkinson-White syndrome and atrioventricular nodal re-entrant tachycardia. J Cardiovasc Pharmacol 1995; 26: 198-206.
5. Wiesfeld A, Crijns H, Bergstrand R, Almgren O, Hillege H. Lie K. Torsades de pointes with almokalant, a new class III antiarrhythmic agent. Am Heart J 1992; 125: 1008-1011.
6. Darpö B, Almgren O, Bergstrand R et al. Tolerance and effects of almokalant, a new selective Ik blocking agent, on ventricular repolarization and on sino - atrial and AV nodal function in the heart: a study in healthy, male volunteers utilizing transesophageal, atrial stimulation. J Cardiovasc Pharmacol 1995; 25: 681-690.
7. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarizations. Cardiovasc Res 1993; 27: 2186-2193.